Does
HIV-HCV Coinfection Increase the Risk of Liver Disease Progression and Worsen
Clinical Outcomes? By
Liz Highleyman A
growing body of evidence indicates that HIV
positive people coinfected with chronic hepatitis C virus (HCV) infection
tend to experience more rapid liver disease progression, although not all studies
have seen this effect, especially among individuals who are taking highly
active antiretroviral therapy (HAART) and have relatively high CD4 cell counts.
The
stream of conflicting data continued at the Digestive Disease
Week (DDW 2009) annual meeting last week in Chicago, with one study finding
no difference in fibrosis
progression between HCV monoinfected and
HIV-HCV coinfected people,
while another showed worse clinical outcomes in coinfected patients. Fibrosis
Progression In
the first study, Frank Grünhage and colleagues from Germany sought to analyze
the effects of HAART on liver
fibrosis progression as assessed by transient elastography (FibroScan). They
performed a cross-sectional comparison between 84 HCV monoinfected and 57 HIV-HCV
coinfected patients presenting at their outpatient clinic. 
Overall,
the investigators stated, they "did not find any difference in the distribution
of liver stiffness" between HCV monoinfected and HIV-HCV coinfected patients
(14.4 vs 12.4 kPa). However, 8 HIV patients with CD4 counts < 200 cells/mm3
had markedly greater liver stiffness than HIV positive individuals with well preserved
immune function (18.4 vs 11.5 kPa). These
findings, they researchers, "confirm an improved prognosis of chronic hepatitis
C in HIV positive patients under effective HAART," and "may be a hint"
that fibrosis progression in well-treated HIV positive patients may no longer
be different from that of HCV monoinfected patients. Medical
Department I, Saarland University Hospital, Homburg, Germany; Department of Internal
Medicine I, University Hospital Bonn, Bonn, Germany; Institute for Experimental
Hemostasiology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany. Clinical
Outcomes In
the second study, Ashwin Ananthakrishnan and colleagues assessed the impact of
HIV-HCV coinfection in a nationally representative cohort of hospitalized patients.
Using data from the 2006 Nationwide Inpatient Sample -- a national database of
hospitalizations from a stratified sample of U.S. community hospitals -- the researchers
identified discharges of patients with HCV, HIV or HIV-HCV coinfection through
corresponding ICD-9 codes. In
total, the study included 474,843 discharges with HCV alone, 206,758 with HIV
alone, and 56,304 with HIV-HCV coinfection. Coinfected patients were younger on
average, more likely to be non-white, and more likely to be on Medicaid than those
with HCV alone; the coinfected patients, however, had a lower comorbidity burden
compared to those with HCV alone. The
primary outcomes of interest were in-hospital mortality, length of stay, and hospitalization
charges. Multivariate regression analysis was performed to determine whether HIV-HCV
coinfection was associated with adverse outcomes. Results
Liver-related admissions were more common among HIV-HCV coinfected patients compared
to those with HIV alone (15.4% vs 3.3%).
However, hospitalization with a primary discharge diagnosis of any infection other
than HIV or HCV was more common among HIV monoinfected patients compared with
coinfected patients.
HIV-HCV coinfection was associated with significantly higher mortality rate compared
with HCV infection alone (odds ratio [OR] 1.41).
While HCV infection by itself did not influence mortality in patients with HIV,
HCV-associated liver cirrhosis or its complications conferred a nearly 4-fold
greater risk of death on people with HIV (OR 3.96).
Taking into account national prevalence estimates for HIV, hepatitis C, and coinfection,
the rate of hospitalization for HIV-HCV coinfected patients (23.5%) was significantly
higher than that of patients with either HCV or HIV alone (14.8% and 19.9%, respectively).
Based
of these findings, the study authors concluded, "HCV-HIV coinfection is associated
with significantly higher rates of hospitalization and is a risk factor for in-hospital
mortality compared to patients with isolated Hepatitis C or HIV infection." Division
of Gastroenterology and Hepatology, Division of Epidemiology, and Division of
Infectious Diseases, Medical College of Wisconsin, Milwaukee, WI. 6/9/09 References F
Grünhage, JC Wasmuth, N Vidovic, and others. Transient Elastography Discloses
Identical Distribution of Liver Fibrosis in Chronic Hepatitis C Between HIV-Negative
and HIV-Positive Patients on HAART. Digestive Disease Week (DDW 2009). Chicago.
May 30-June 4, 2009. Abstract M1713. AN
Ananthakrishnan, EL McGinley, J Fangman, and K Saeian. Hepatitis C-HIV Co-Infection
Is a Risk Factor for Worse Outcomes in Hospitalized Patients: a National Study.
Digestive Disease Week (DDW 2009). Chicago. May 30-June 4, 2009. Abstract M1765.
|